Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
SR One Capital Management, LP (CIK 1910264) reported $915.4M across 13 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: ACLX ($269.4M, 29.43%), ($151.7M, 16.57%), ZBIO ($98.5M, 10.76%), CRSP ($97.0M, 10.59%), DSGN ($69.4M, 7.59%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | ACLX | Arcellx, Inc. | $269.4M | 29.43% | 2.3M | Hold |
| 2 | Veradermics, Inc. | $151.7M | 16.57% | 2.4M | New | |
| 3 | ZBIO | Zenas BioPharma, Inc | $98.5M | 10.76% | 5.0M | Hold |
| 4 | CRSP | CRISPR Therapeutics AG | $97.0M | 10.59% | 2.0M | Hold |
| 5 | DSGN | Design Therapeutics, Inc. | $69.4M | 7.59% | 6.5M | Hold |
| 6 | ORIC | ORIC Pharmaceuticals, Inc. | $58.5M | 6.39% | 4.5M | Hold |
| 7 | ALMS | Alumis Inc. | $43.2M | 4.72% | 2.0M | Hold |
| 8 | MLYS | Mineralys Therapeutics Inc. | $42.4M | 4.63% | 1.6M | Hold |
| 9 | SPRY | ARS Pharmaceuticals, Inc. | $32.2M | 3.52% | 4.0M | Hold |
| 10 | ORKA | Oruka Therapeutics, Inc | $21.1M | 2.31% | 430,330 | Hold |
| 11 | OCS | Oculis Holding AG | $17.0M | 1.86% | 641,022 | Hold |
| 12 | NKTX | Nkarta, Inc. | $7.0M | 0.77% | 3.3M | Hold |
| 13 | ENGN | enGene Holdings Inc. | $5.1M | 0.56% | 747,750 | Hold |
| 14 | RARE | Ultragenyx Pharmaceutical Inc. | $2.9M | 0.32% | 137,753 | Hold |
Source: SEC Form 13F filings · as of 2026-03-31